Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000401174

Medchemexpress LLC Naquotinib mesylate | 1448237-05-5 | 98.06% | 658.81 | 50 MG
SDP

Catalog No. 5000401174
Encompass_Preferred

Naquotinib mesylate is an orally available, mutant-selective and irreversible EGFR inhibitor. It shows potent inhibition against EGFR mutants with IC50s of 8-33 nM, and 230 nM for wild-type EGFR. It has demonstrated efficacy in inhibiting cell growth and inducing tumor regression in various xenograft models.

  • Orally available and mutant-selective
  • Irreversible EGFR inhibitor
  • Potent inhibition of EGFR mutants (8-33 nM IC50)
  • Inhibits phosphorylation of EGFR and downstream signaling pathways (ERK and Akt)
  • Induces tumor regression in xenograft models

Catalog No. 50-004-01174 Supplier Medchemexpress LLC Supplier No. HY1980350MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Naquotinib mesylate is an orally available, mutant-selective and irreversible EGFR inhibitor. It shows potent inhibition against EGFR mutants with IC50s of 8-33 nM, and 230 nM for wild-type EGFR. It has demonstrated efficacy in inhibiting cell growth and inducing tumor regression in various xenograft models.

  • Orally available and mutant-selective
  • Irreversible EGFR inhibitor
  • Potent inhibition of EGFR mutants (8-33 nM IC50)
  • Inhibits phosphorylation of EGFR and downstream signaling pathways (ERK and Akt)
  • Induces tumor regression in xenograft models

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.